Germany Post-Traumatic Stress Disorder (PTSD) Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Germany Post-Traumatic Stress Disorder (PTSD) market is projected to register a substantial CAGR of 4.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Germany Post-Traumatic Stress Disorder (PTSD) Market, By Type (Medication (antidepressant, antipsychotics), Psychotherapy, Software Devices), Route of Administration (Oral, Parenteral, and Others), Age Group (Children, Adults, Geriatric), End User (Hospitals, Outpatient Clinics, Mental Health Centers, Home HealthCare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of Germany Post-Traumatic Stress Disorder (PTSD) Market are:

Rising prevalence of PTSD

Technological advancements in the diagnosis and treatment of PTSD

Market Players:

Some of the major players operating in the Germany Post-Traumatic Stress Disorder (PTSD) Market are:

AbbVie Inc.

Viatris Inc

Pfizer Inc.

Eli Lilly and Company

Takeda Pharmaceutical Company Limited

Aurobindo Pharma.

AstraZeneca

Cipla Inc.

Lupin

Accord Healthcare GmbH

Dr. Reddy's Laboratories Ltd.

Zydus Pharmaceuticals, Inc.

GlaxoSmithKline Group of Companies.

Teva Pharmaceutical Industries Ltd.

Alkermes.

Novartis AG., among others.

1 INTRODUCTION 13

1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET 13
1.4 CURRENCY AND PRICING 15
1.5 LIMITATIONS 15
1.6 MARKETS COVERED 15

2 MARKET SEGMENTATION 18

2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 19
2.4 DBMR TRIPOD DATA VALIDATION MODEL 20
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23
2.6 MULTIVARIATE MODELLING 24
2.7 TYPE LIFELINE CURVE 24
2.8 MARKET APPLICATION COVERAGE GRID 25
2.9 DBMR MARKET POSITION GRID 26
2.10 VENDOR SHARE ANALYSIS 27
2.11 SECONDARY SOURCES 28
2.12 ASSUMPTIONS 28

3 EXECUTIVE SUMMARY 29

3.1 MERGERS AND ACQUISITION 32
3.2 PIPELINE ANALYSIS FOR GERMANY POST-TRAUMATIC STRESS DISORDER MARKET 33
- 3.2.1 RECENT APPROVALS 34
3.3 PESTEL ANALYSIS 35
3.4 PORTER'S FIVE FORCES MODEL 36

4 REGULATIONS OF GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET 37

4.1 REGULATORY AND DRUG APPROVAL SCENARIO IN GERMANY 37
4.2 APPROVAL FRAMEWORK 37
- 4.2.1 CLINICAL PRACTICE 38
- 4.2.2 MARKETING AUTHORIZATION 38

5 INDUSTRY INSIGHTS 41

5.1 PATENT ANALYSIS 41
- 5.1.1 DRUG TREATMENT RATE BY MATURED MARKETS 41
- 5.1.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 41
- 5.1.3 KEY PRICING STRATEGIES 42
- 5.1.4 KEY PATIENT ENROLLMENT STRATEGIES 42

6 EPIDEMIOLOGY 43

6.1 HISTORIC PTSD POOL 43
6.2 PRESENT PTSD POOL 43
6.3 FURURE PTSD POOL 43
6.4 PREVALENCE OF DISSOCIATIVE PTSD BY COUNTRY 44
6.5 PREVALENCE OF UNCOMPLICATED PTSD BY COUNTRY 44
6.6 PREVALENCE OF COMORBID PTSD BY COUNTRY 44
6.7 TREATMENT RATE 45

7 INTRODUCTION 46

7.1 OVERVIEW 46
7.2 IMPACT OF UKRAINE AND RUSSIA WAR ON GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET 46
7.3 IMPACT ANALYSIS ON DEMAND 46
7.4 CONCLUSION 47

8 MARKET OVERVIEW 48

8.1 DRIVERS 50
- 8.1.1 RISING PREVALENCE OF PTSD. 50
- 8.1.2 TECHNOLOGICAL ADVANCEMENTS IN THE DIAGNOSIS AND TREATMENT OF PTSD. 50
- 8.1.3 THE INCREASING INCIDENCE OF PTSD 50
- 8.1.4 INCREASED AWARENESS AMONG PATIENTS AND DOCTORS REGARDING THERAPIES FOR PTSD 51
8.2 RESTRAINTS 51
- 8.2.1 HIGH COST OF THE TREATMENT 51
- 8.2.2 SIDE EFFECTS ASSOCIATED WITH PTSD TREATMENT. 52
8.3 OPPORTUNITIES 52
- 8.3.1 RISING HEALTHCARE EXPENDITURE 52
- 8.3.2 RISING APPROVALS OF DRUGS 52
- 8.3.3 THE RISING NUMBER OF CLINICAL TRIALS IS EXPECTED TO BOOST THE GROWTH OF THE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET 53
8.4 CHALLENGES 53
- 8.4.1 PATENT EXPIRY OF DRUGS 53
- 8.4.2 RISING ALTERNATIVE THERAPIES 54
8.5 UNMEET NEEDS 54
- 8.5.1 UNMEET REIMBURSEMENT COST 54
- 8.5.2 MENTAL HEALTH STATUS AND SOCIAL CONDITIONS OF ASYLUM SEEKERS 55

9 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TYPE 56

9.1 OVERVIEW 57
9.2 UNCOMPLICATED PTSD 60
9.3 DISSOCIATIVE PTSD 60
9.4 COMORBID PTSD 60
9.5 OTHERS 61

10 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT 62

10.1 OVERVIEW 63
10.2 PSYCHOTHERAPY 66
- 10.2.1 COGNITIVE BEHAVIORAL THERAPY 67
- 10.2.2 FAMILY THERAPY 67
- 10.2.3 STRESS INOCULATION THERAPY 67
- 10.2.4 PROLONGED EXPOSURE THERAPY 67
- 10.2.5 OTHERS 67
10.3 MEDICATION 67
- 10.3.1 ANTIDEPRESSANTS 68
  - 10.3.1.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS 68
    - 10.3.1.1.1 SERTRALINE 69
    - 10.3.1.1.2 PAROXETINE 69
    - 10.3.1.1.3 FLUOXETINE 69
    - 10.3.1.1.4 CITALOPRAM 69
    - 10.3.1.1.5 NEFAZODONE 69
    - 10.3.1.1.6 OTHERS 69
  - 10.3.1.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS 70
    - 10.3.1.2.1 DULOXETINE 70
    - 10.3.1.2.2 VENLAFAXINE 70
    - 10.3.1.2.3 OTHERS 70
  - 10.3.1.3 TRICYCLIC ANTIDEPRESSANTS 70
    - 10.3.1.3.1 AMITRIPTYLINE 71
    - 10.3.1.3.2 IMIPRAMINE 71
    - 10.3.1.3.3 OTHERS 71
- 10.3.2 ANTIPSYCHOTICS 71
  - 10.3.2.1 QUETIAPINE 72
  - 10.3.2.2 ARIPIPRAZOLE 72
  - 10.3.2.3 DIVALPROEX 72
  - 10.3.2.4 LAMOTRIGINE 72
  - 10.3.2.5 OTHERS 72
- 10.3.3 OTHERS 72
10.4 SOFTWARE DEVICES 72
- 10.4.1 PTSD COACH 73
- 10.4.2 PE COACH 73
- 10.4.3 CPT COACH 73
- 10.4.4 OTHERS 73

11 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET , BY ROUTE OF ADMINISTRATION 74

11.1 OVERVIEW 75
11.2 ORAL 78
11.3 PARENTERAL 78
11.4 OTHERS 78

12 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY AGE GROUP 79

12.1 OVERVIEW 80
12.2 ADULTS 83
12.3 GERIATRICS 83
12.4 CHILDREN 84

13 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY END USER 85

13.1 OVERVIEW 86
13.2 MENTAL HEALTH CENTERS 89
13.3 HOSPITALS 89
13.4 OUTPATIENT CLINICS 89
13.5 HOME HEALTHCARE 90
13.6 OTHERS 90

14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY DISTRIBUTION CHANNEL 91

14.1 OVERVIEW 92
14.2 HOSPITAL PHARMACY 95
14.3 RETAIL PHARMACY 95
14.4 ONLINE PHARMACY 95
14.5 OTHERS 96

15 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: COMPANY LANDSCAPE 97

15.1 COMPANY SHARE ANALYSIS: GERMANY 97

16 SWOT ANALYSIS 98

17 COMPANY PROFILE 99

17.1 ABBVIE (2022) 99
- 17.1.1 COMPANY SNAPSHOT 99
- 17.1.2 REVENUE ANALYSIS 99
- 17.1.3 PRODUCT PORTFOLIO 100
- 17.1.4 RECENT DEVELOPMENT 100
17.2 VIATRIS INC. (2022) 101
- 17.2.1 COMPANY SNAPSHOT 101
- 17.2.2 REVENUE ANALYSIS 101
- 17.2.3 PRODUCT PORTFOLIO 102
17.3 PFIZER INC 103
- 17.3.1 COMPANY SNAPSHOT 103
- 17.3.2 REVENUE ANALYSIS 104
- 17.3.3 PRODUCT PORTFOLIO 104
- 17.3.4 RECENT DEVELOPMENTS 104
- 17.3.5 RECENT DEVELOPMENT 104
17.4 ELI LILLY AND COMPANY (2022) 105
- 17.4.1 COMPANY SNAPSHOT 105
- 17.4.2 REVENUE ANALYSIS 105
- 17.4.3 PRODUCT PORTFOLIO 106
- 17.4.4 RECENT DEVELOPMENT 106
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2022) 107
- 17.5.1 COMPANY SNAPSHOT 107
- 17.5.2 REVENUE ANALYSIS 107
- 17.5.3 PRODUCT PORTFOLIO 108
- 17.5.4 RECENT DEVELOPMENT 108
17.6 ACCORD HEALTHCARE GMBH. 109
- 17.6.1 COMPANY SNAPSHOT 109
- 17.6.2 PRODUCT PORTFOLIO 109
- 17.6.3 RECENT DEVELOPMENTS 109
17.7 ALKERMES. 110
- 17.7.1 COMPANY SNAPSHOT 110
- 17.7.2 REVENUE ANALYSIS 110
- 17.7.3 PRODUCT PORTFOLIO 111
- 17.7.4 RECENT DEVELOPMENTS 111
17.8 ASTRAZENECA (2022) 112
- 17.8.1 COMPANY SNAPSHOT 112
- 17.8.2 REVENUE ANALYSIS 112
- 17.8.3 PRODUCT PORTFOLIO 113
- 17.8.4 RECENT DEVELOPMENT 113
17.9 AUROBINDO PHARMA. 114
- 17.9.1 COMPANY SNAPSHOT 114
- 17.9.2 REVENUE ANALYSIS 115
- 17.9.3 PRODUCT PORTFOLIO 115
- 17.9.4 RECENT DEVELOPMENTS 115
17.10 CIPLA INC. (2022) 116
- 17.10.1 COMPANY SNAPSHOT 116
- 17.10.2 REVENUE ANALYSIS 116
- 17.10.3 PRODUCT PORTFOLIO 117
- 17.10.4 RECENT DEVELOPMENT 117
17.11 DR. REDDY'S LABORATORIES LTD 118
- 17.11.1 COMPANY SNAPSHOT 118
- 17.11.2 REVENUE ANALYSIS 118
- 17.11.3 PRODUCT PORTFOLIO 119
- 17.11.4 RECENT DEVELOPMENTS 119
17.12 GLAXOSMITHKLINE GROUP OF COMPANIES. 120
- 17.12.1 COMPANY SNAPSHOT 120
- 17.12.2 REVENUE ANALYSIS 120
- 17.12.3 PRODUCT PORTFOLIO 121
- 17.12.4 RECENT DEVELOPMENTS 121
17.13 LUPIN (2022) 122
- 17.13.1 COMPANY SNAPSHOT 122
- 17.13.2 REVENUE ANALYSIS 122
- 17.13.3 PRODUCT PORTFOLIO 123
- 17.13.4 RECENT DEVELOPMENT 123
17.14 NOVARTIS AG 124
- 17.14.1 COMPANY SNAPSHOT 124
- 17.14.2 REVENUE ANALYSIS 124
- 17.14.3 PRODUCT PORTFOLIO 125
- 17.14.4 RECENT DEVELOPMENTS 125
17.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. 126
- 17.15.1 COMPANY SNAPSHOT 126
- 17.15.2 REVENUE ANALYSIS 126
- 17.15.3 PRODUCT PORTFOLIO 127
- 17.15.4 RECENT DEVELOPMENTS 127
17.16 ZYDUS PHARMACEUTICALS, INC. (2022) 128
- 17.16.1 COMPANY SNAPSHOT 128
- 17.16.2 REVENUE ANALYSIS 128
- 17.16.3 PRODUCT PORTFOLIO 129
- 17.16.4 RECENT DEVELOPMENT 129

18 QUESTIONNAIRE 130

19 RELATED REPORTS 133

LIST OF TABLES

TABLE 1 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TYPE, 2021-2030 (USD MILLION) 59
TABLE 2 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 65
TABLE 3 GERMANY PSYCHOTHERAPY IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 66
TABLE 4 GERMANY MEDICATION IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 68
TABLE 5 GERMANY ANTIDEPRESSANTS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 68
TABLE 6 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 69
TABLE 7 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 70
TABLE 8 GERMANY TRICYCLIC ANTIDEPRESSANTS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 71
TABLE 9 GERMANY ANTIPSYCHOTICS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 71
TABLE 10 GERMANY SOFTWARE DEVICES IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 73
TABLE 11 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 77
TABLE 12 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 82
TABLE 13 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY END USER, 2021-2030 (USD MILLION) 88
TABLE 14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 94

LIST OF FIGURES

FIGURE 1 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : SEGMENTATION 18
FIGURE 2 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DATA TRIANGULATION 20
FIGURE 3 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DROC ANALYSIS 21
FIGURE 4 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 22
FIGURE 5 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : COMPANY RESEARCH ANALYSIS 22
FIGURE 6 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : INTERVIEW DEMOGRAPHICS 23
FIGURE 7 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : MARKET APPLICATION COVERAGE GRID 25
FIGURE 8 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DBMR MARKET POSITION GRID 26
FIGURE 9 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : VENDOR SHARE ANALYSIS 27
FIGURE 10 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : SEGMENTATION 30
FIGURE 11 INCREASING PREVALENCE OF POST-TRAUMATIC STRESS DISORDER IN POPULATION ARE EXPECTED TO DRIVE THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET IN THE FORECAST PERIOD 31
FIGURE 12 UNCOPLICATED PTSD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET IN 2023 & 2030 31
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET 49
FIGURE 14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, 2022 57
FIGURE 15 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, 2023-2030 (USD MILLION) 58
FIGURE 16 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, CAGR (2023-2030) 58
FIGURE 17 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, LIFELINE CURVE 59
FIGURE 18 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, 2022 63
FIGURE 19 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, 2023-2030 (USD MILLION) 64
FIGURE 20 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, CAGR (2023-2030) 64
FIGURE 21 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, LIFELINE CURVE 65
FIGURE 22 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, 2022 75
FIGURE 23 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 76
FIGURE 24 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 76
FIGURE 25 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 77
FIGURE 26 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, 2022 80
FIGURE 27 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 81
FIGURE 28 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, CAGR (2023-2030) 81
FIGURE 29 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, LIFELINE CURVE 82
FIGURE 30 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, 2022 86
FIGURE 31 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, 2023-2030 (USD MILLION) 87
FIGURE 32 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, CAGR (2023-2030) 87
FIGURE 33 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, LIFELINE CURVE 88
FIGURE 34 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, 2022 92
FIGURE 35 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 93
FIGURE 36 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 93
FIGURE 37 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
FIGURE 38 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: COMPANY SHARE 2022 (%) 97